摘要
目的:探究布拉氏酵母菌散联合四联疗法治疗幽门螺杆菌阳性慢性胃炎患者的临床效果及安全性。方法:选取2021年8月—2022年10月福州市伽禾伽美医院消化内科收治的204例幽门螺杆菌阳性慢性胃炎患者。根据病历号信封随机抽签法将其分为研究组和对照组,各102例。对照组给予四联疗法治疗,研究组给予布拉氏酵母菌散联合四联疗法治疗。比较两组治疗前、治疗结束后28 d(治疗后)炎症因子、临床症状积分,幽门螺杆菌根除情况、临床疗效及不良反应。结果:治疗后,研究组白细胞介素-17(IL-17)、γ干扰素(INF-γ)水平均显著低于对照组,差异有统计学意义(P<0.05)。治疗后,研究组胃部灼痛、饱胀感、嗳气、反酸评分均显著低于对照组,差异有统计学意义(P<0.05)。研究组幽门螺杆菌根除率显著高于对照组,差异有统计学意义(P<0.05)。研究组总有效率显著高于对照组,差异有统计学意义(P<0.05)。研究组不良反应发生率显著低于对照组,差异有统计学意义(P<0.05)。结论:幽门螺杆菌阳性慢性胃炎患者采用布拉氏酵母菌散联合四联疗法治疗可降低体内炎症因子水平,缓解临床症状,提高幽门螺杆菌根除率,改善治疗效果,降低不良反应发生率。
Objective:To explore the clinical effect and safety of Saccharomyces Boulardii Sachets combined with quadruple therapy in the treatment of chronic gastritis patients with Helicobacter pylori positive.Method:A total of 204 patients with chronic gastritis with Helicobacter pylori positive were selected from the Gastroenterology Department of Jahous General Hospital of Fuzhou from August 2021 to October 2022.They were divided into study group and control group according to the random drawing method of medical record number envelope,with 102 cases in each group.The control group was treated with quadruple therapy,and the study group was treated with Saccharomyces Boulardii Sachets combined with quadruple therapy.Inflammatory factors,clinical symptom scores before treatment and 28 days after treatment(after treatment),Helicobacter pylori eradication condition,clinical efficacy and adverse reactions were compared between the two groups.Result:After treatment,the levels of interleukin-17(IL-17)and interferon-γ(INF-γ)in the study group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the scores of heartburn in the stomach,feeling of fullness,belching and acid reflux in the study group were significantly lower than those in the control group,the differences were statistically significant(P<0.05).The eradication rate of Helicobacter pylori in the study group was significantly higher than that in the control group,the difference was statistically significant(P<0.05).The total effective rate of the study group was significantly higher than that of the control group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the study group was significantly lower than that in the control group,the difference was statistically significant(P<0.05).Conclusion:The treatment of Helicobacter pylori positive chronic gastritis patients with the Saccharomyces Boulardii Sachets combined with quadruple therapy can reduce
作者
詹剑勇
袁湘庭
苏少辉
ZHAN Jianyong;YUAN Xiangting;SU Shaohui(Jahous General Hospital of Fuzhou,Fuzhou 350005,China;不详)
出处
《中外医学研究》
2023年第25期59-63,共5页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
益生菌
铋剂
四联疗法
幽门螺杆菌
慢性胃炎
Probiotics
Bismuth agent
Quadruple therapy
Helicobacter pylori
Chronic gastritis
